Emergent Biosolutions Inc. (NYSE:EBS) shares shot up 5.2% during mid-day trading on Wednesday . The company traded as high as $32.00 and last traded at $31.89, with a volume of 197,348 shares trading hands. The stock had previously closed at $30.30.

A number of brokerages have issued reports on EBS. Cowen and Company restated a “buy” rating on shares of Emergent Biosolutions in a research note on Sunday, April 17th. Chardan Capital restated a “buy” rating on shares of Emergent Biosolutions in a research note on Monday, May 2nd. Zacks Investment Research lowered shares of Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 2nd. Singular Research cut their price target on shares of Emergent Biosolutions from $44.00 to $40.00 and set a “buy” rating on the stock in a research note on Tuesday, June 28th. Finally, Wells Fargo & Co. restated a “buy” rating on shares of Emergent Biosolutions in a research note on Wednesday, June 22nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $42.75.

The firm has a 50 day moving average price of $34.80 and a 200-day moving average price of $36.62. The firm has a market cap of $1.29 billion and a PE ratio of 17.26.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported $0.16 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.07) by $0.23. The business earned $111 million during the quarter, compared to analysts’ expectations of $101.83 million. During the same period in the previous year, the business posted ($0.50) EPS. The company’s revenue for the quarter was up 74.5% compared to the same quarter last year. Equities research analysts forecast that Emergent Biosolutions Inc. will post $1.45 EPS for the current fiscal year.

In related news, Director Louis W. Sullivan sold 9,969 shares of Emergent Biosolutions stock in a transaction that occurred on Wednesday, May 11th. The shares were sold at an average price of $39.25, for a total value of $391,283.25. Following the completion of the transaction, the director now owns 38,469 shares in the company, valued at $1,509,908.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director George A. Joulwan sold 4,700 shares of Emergent Biosolutions stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $44.12, for a total transaction of $207,364.00. Following the completion of the transaction, the director now owns 20,785 shares of the company’s stock, valued at approximately $917,034.20. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have recently modified their holdings of EBS. Eagle Asset Management increased its position in shares of Emergent Biosolutions by 143.9% in the third quarter. Eagle Asset Management now owns 1,245,128 shares of the biopharmaceutical company’s stock worth $35,472,000 after buying an additional 734,578 shares in the last quarter. Matarin Capital Management LLC purchased a new position in shares of Emergent Biosolutions during the fourth quarter worth about $7,953,000. Dimensional Fund Advisors LP increased its position in shares of Emergent Biosolutions by 6.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,911,645 shares of the biopharmaceutical company’s stock worth $76,485,000 after buying an additional 112,452 shares in the last quarter. Bank of Montreal Can increased its position in shares of Emergent Biosolutions by 346.9% in the fourth quarter. Bank of Montreal Can now owns 93,100 shares of the biopharmaceutical company’s stock worth $3,725,000 after buying an additional 72,266 shares in the last quarter. Finally, Aberdeen Asset Management PLC UK increased its position in shares of Emergent Biosolutions by 25.2% in the fourth quarter. Aberdeen Asset Management PLC UK now owns 342,726 shares of the biopharmaceutical company’s stock worth $10,304,000 after buying an additional 69,026 shares in the last quarter.

Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.